Table 3.

Radiographic, pathologic and molecular response characteristics

Patient number	Radiographic response*	Residual tumor (%)	Pre-treatment PD-L1 (%)	Normalized tumor mutation burden	Driver genes with sequence alterations
1	PD	100	0	344	KRAS, STK11
2	PD†	N/A	1	109	KRAS, KEAP1, STK11
3	SD	90	10	147	KRAS, STK11, TP53
4	PD	N/A	1	63	KRAS, KEAP1, STK11
5	PR	0 (pCR)	75	554	KRAS, STK11
6	SD	0 (pCR)	95	Undeterminable‡	Undeterminable‡
7	SD	70	0	914	TP53
8	PD	N/A	0	78	BRAF, STK11, TP53
9	SD	20	30	99	TP53

*All radiographic RECIST assessments were unconfirmed, as only one post-neoadjuvant treatment imaging assessment was made prior to surgical resection.

†Clear metastatic disease on PET imaging despite stable disease on RECIST response assessment of chest CT and thus coded as having “PD”.

‡Pre-treatment tumor tissue for patient 6 was insufficient for whole exome sequencing and thus genomic assessments could not be performed.

N/A, not applicable; pCR, pathologic complete response; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease.